文献速递前列腺癌

前列腺癌影像学:前列腺特异性膜抗原的临床效用

Imaging Prostate Cancer: Clinical Utility of Prostate-Specific Membrane Antigen.
PubMed 文献 · J Urol · 2022-01-27

本文综述了前列腺特异性膜抗原(PSMA)扫描获得美国食品药品监督管理局(FDA)批准的路径及相关材料,聚焦4项大型美国试验(镓-68化合物大学研究与氟-18化合物商业研究),并关注PSMA扫描在前列腺癌初始分期和复发诊断中的作用。结论认为PSMA扫描是一项颠覆性技术,有望改变前列腺癌初始分期、复发诊断及部分晚期病例治疗的方式。

要点

  • PSMA扫描的灵敏度和特异度超过目前可用的任何其他影像方法。
  • PSMA扫描的高准确度归因于高信噪比带来的优异图像对比度。
  • 后续PSMA化合物镥-177目前正待FDA批准用于转移灶治疗。

核心结论

  • PSMA扫描是一项颠覆性技术,有望改变前列腺癌初始分期、复发诊断及部分晚期病例治疗的方式。

研究设计与样本

  • 本综述从关键试验入手并回溯,总结PSMA扫描的演变过程,聚焦PubMed®上数千篇PSMA文章中4项大型美国试验(镓-68化合物大学研究和氟-18化合物商业研究),并关注PSMA扫描在前列腺癌初始分期和复发诊断中的作用。

主要发现

  • PSMA是一种跨膜糖蛋白,在前列腺癌细胞中过表达100至1000倍。
  • 20世纪90年代康奈尔和约翰霍普金斯大学的临床前PSMA研究之后,2010年代初德国开展了早期人体研究,随后加州大学洛杉矶分校和加州大学旧金山分校的关键临床试验促成了2020年12月首次FDA批准(68Ga-PSMA-11)。
  • 2021年1月,基于多中心注册试验(CONDOR和OSPREY)批准了商业可用的产品(18F-DCFPyL)。
  • PSMA扫描的灵敏度和特异度超过目前可用的任何其他影像方法,用于前列腺癌初始分期和复发诊断。
  • PSMA扫描的准确度归因于高信噪比带来的优异图像对比度,该特性源于前列腺癌细胞对PSMA示踪剂的高摄取,可通过标准化摄取值这一指标定量估计。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our goal was to review the pathway and pertinent materials leading to approval of prostate-specific membrane antigen (PSMA) scanning by the U.S. Food and Drug Administration (FDA). MATERIALS AND METHODS: Beginning with the pivotal trials and working backward, we summarize the evolution of PSMA scanning, beginning with the discovery of the molecule, the mechanism of action to identify prostate cancer, the route to the present-day test and some of the major publications leading to each step of the sequence. From the thousands of PSMA articles listed on PubMed®, the present review is focused on the 4 large U.S. trials incorporating university studies of the gallium-68 compound and commercial studies of the fluorine-18 compound. The review further focuses on the role of PSMA scanning for both initial staging of prostate cancer and diagnosis of recurrent prostate cancer. RESULTS: PSMA is a transmembrane-bound glycoprotein which is overexpressed by 100-1,000-fold in prostate cancer cells. Preclinical PSMA studies at Cornell and Johns Hopkins in the 1990s were followed by early human studies in Germany in the early 2010s, then pivotal clinical trials at University of California, Los Angeles and University of California, San Francisco, leading to the first FDA approval in December 2020 (68Ga-PSMA-11). In January 2021, a commercially available product (18F-DCFPyL) was approved on the basis of multisite registration trials (CONDOR and OSPREY). Sensitivity and specificity of PSMA scanning exceeds that of any other imaging method currently available for initial staging of prostate cancer and diagnosis of recurrent disease. The accuracy of PSMA scanning is attributed to the great image contrast (high signal-to-noise ratio), a property deriving from the high PSMA tracer uptake by prostate cancer cells. That property can be estimated quantitatively by a metric, the standardized uptake value. A follow-on PSMA compound, the theranostic lutetium-177, is currently pending FDA approval for treatment of metastases. CONCLUSIONS: PSMA scanning is a disruptive technology that promises to transform the way prostate cancer is initially staged, recurrence is diagnosed and some advanced cases are treated.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Kuppermann D, Calais J, Marks LS, et al. Imaging Prostate Cancer: Clinical Utility of Prostate-Specific Membrane Antigen. J Urol. 2022. PMID: 35085002. doi:10.1097/JU.0000000000002457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。